Adeona's Alzheimer's Disease Pivotal Clinical Study Results Abstract Accepted for Presentation at the American Academy of Neurology's 63rd Annual Meeting
ANN ARBOR, Mich., Feb. 8, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that an abstract on the Company's pivotal clinical trial of its zinc and cysteine-based product candidate being evaluated in patients with Alzheimer's disease and mild cognitive impairment has been accepted for presentation at the 2011 American Academy of Neurology Annual Meeting in April. The abstract will provide top line clinical trial results, as well as the rationale and design of the pivotal study.
Diana Pollock, M.D., Lead Principal Investigator of the trial at Morton Plant Neuroscience Institute on the campus of Morton Plant Hospital, is the first author on the abstract titled "Clinical Trial Results of the First Controlled Clinical Trial of Zinc-Based Therapy for Alzheimer's Disease and Mild Cognitive Impairment." The poster presentation will be held from 2:00 to 6:30 p.m. on April 14, 2011 at the Hawaii Convention Center in Honolulu, Hawaii. Due to conference restrictions with regard to the embargo policy relating to clinical trial results, Adeona plans to present the results of its pivotal clinical trial during this conference and distribute a concurrent press release.
Adeona also announced that "reaZin™" has been adopted as the new trademark for its zinc and cysteine-based oral tablet currently under development as a prescription medical food for the dietary management of Alzheimer's disease and mild cognitive impairment. Previously, Adeona's zinc and cysteine-based product candidate was called Zinthionein.
reaZin was selected as the new trademark as it is a homophone to the word reason, a high level cognitive function affected by Alzheimer's disease that Adeona's product candidate seeks to address. In addition, the "Zin" root is suggestive of the p